Publication | Closed Access

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Disease ProgressionFirst-dose EffectsClinical TrialsTreatment OptionOutcomes ResearchRandomized Controlled TrialPharmacotherapyNeurologyMultiple SclerosisEvaluate Patient OutcomesMedicine